{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T20:23:02Z","timestamp":1773087782846,"version":"3.50.1"},"reference-count":65,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Although two targeted therapies have received recent approval for systemic sclerosis (SSc)-associated interstitial lung disease, they do not show major disease-modifying activity, highlighting the need for novel therapies and innovative paradigms. To that end, cellular therapies may represent a new opportunity for the treatment of SSc. The purpose of this review is to provide an up-to-date overview of emerging cell-based disease-modifying therapies in SSc.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Initial small studies in patients with severe refractory systemic lupus erythematosus (SLE) using engineered regulatory cells show promising results. CD19-directed CAR-T have shown promising results in one case report of refractory diffuse cutaneous SSc patients. T cells engineered to express a chimeric autoantibody receptor (CAAR-T cells) may be even more relevant via the specific elimination of auto-reactive B cells. Targeting pro-fibrotic or senescence-related pathways may also constitute promising approaches in SSc.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Building on the classification of the clinical phenotype and prediction of clinical trajectory based on individual patients\u2019 autoantigen and\/or autoantibody profile, cellular therapies targeting the same autoantigen or related autoreactive cells may represent an unprecedented opportunity to implement personalized medicine in SSc.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000970","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T16:26:15Z","timestamp":1693499175000},"page":"356-363","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Emerging cellular and immunotherapies for systemic sclerosis: from mesenchymal stromal cells to CAR-T cells and vaccine-based approaches"],"prefix":"10.1097","volume":"35","author":[{"given":"Alain","family":"Lescoat","sequence":"first","affiliation":[{"name":"University of Rennes CHU Rennes, Inserm, EHESP, Irset -Institut de Recherche en Sant\u00e9, Environnement et Travail-UMRS"},{"name":"Department of Internal Medicine and Clinical Immunology, CHU Rennes, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kato","sequence":"additional","affiliation":[{"name":"University of Michigan Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Varga","sequence":"additional","affiliation":[{"name":"University of Michigan Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12016-021-08891-0","article-title":"Therapeutic approaches to systemic sclerosis: recent approvals and future candidate therapies","volume":"64","author":"Lescoat","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.41933","article-title":"Systemic sclerosis-associated interstitial lung disease: how to incorporate two Food and Drug Administration-approved therapies in clinical practice","volume":"74","author":"Khanna","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"102755","DOI":"10.1016\/j.autrev.2021.102755","article-title":"Mesenchymal stromal cells for systemic sclerosis treatment","volume":"20","author":"Farge","year":"2021","journal-title":"Autoimmun Rev"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1038\/s41467-021-26834-3","article-title":"Mesenchymal stromal cell apoptosis is required for their therapeutic function","volume":"12","author":"Pang","year":"2021","journal-title":"Nat Commun"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/BOR.0000000000000835","article-title":"Contribution of monocytes and macrophages to the pathogenesis of systemic sclerosis: recent insights and therapeutic implications","volume":"33","author":"Lescoat","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"114103","DOI":"10.1016\/j.bcp.2020.114103","article-title":"Combined antifibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: perspectives for scleroderma-associated interstitial lung disease","volume":"178","author":"Lescoat","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"e020479","DOI":"10.1136\/bmjopen-2017-020479","article-title":"A randomised placebo-controlled double-blind trial to assess the safety of intramuscular administration of allogeneic mesenchymal stromal cells for digital ulcers in systemic sclerosis: the MANUS Trial protocol","volume":"8","author":"van Rhijn-Brouwer","year":"2018","journal-title":"BMJ Open"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/art.39477","article-title":"Antifibrotic, antioxidant, and immunomodulatory effects of mesenchymal stem cells in HOCl-induced systemic sclerosis","volume":"68","author":"Maria","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaut.2016.03.013","article-title":"Human adipose mesenchymal stem cells as potent antifibrosis therapy for systemic sclerosis","volume":"70","author":"Maria","year":"2016","journal-title":"J Autoimmun"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41420-022-01264-2","article-title":"Mesenchymal stem cells alleviate systemic sclerosis by inhibiting the recruitment of pathogenic macrophages","volume":"8","author":"Gong","year":"2022","journal-title":"Cell Death Discov"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13075-022-02915-6","article-title":"Therapeutic effects of adipose-derived mesenchymal stem\/stromal cells with enhanced migration ability and hepatocyte growth factor secretion by low-molecular-weight heparin treatment in bleomycin-induced mouse models of systemic sclerosis","volume":"24","author":"Suzuka","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00441-022-03716-8","article-title":"Mesenchymal stem cells suppressed skin and lung inflammation and fibrosis in topoisomerase I-induced systemic sclerosis associated with lung disease mouse model","volume":"391","author":"Ganesan","year":"2023","journal-title":"Cell Tissue Res"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.3390\/cells10102727","article-title":"Lung fibrosis is improved by extracellular vesicles from IFN\u03b3-primed mesenchymal stromal cells in murine systemic sclerosis","volume":"10","author":"Rozier","year":"2021","journal-title":"Cells"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/S2665-9913(21)00326-X","article-title":"Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1\/2 study","volume":"4","author":"Farge","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/stcltm\/szad010","article-title":"Regulatory B cells contribute to the clinical response after bone marrow-derived mesenchymal stromal cell infusion in patients with systemic sclerosis","volume":"12","author":"Loisel","year":"2023","journal-title":"Stem Cells Transl Med"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/13543784.2021.1923693","article-title":"New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine","volume":"30","author":"Lescoat","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.4049\/jimmunol.179.5.3351","article-title":"Depletion of B cells in murine lupus: efficacy and resistance","volume":"179","author":"Ahuja","year":"2007","journal-title":"J Immunol"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","article-title":"Targeting cardiac fibrosis with engineered T cells","volume":"573","author":"Aghajanian","year":"2019","journal-title":"Nature"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/BOR.0000000000000898","article-title":"Role of cellular senescence in the pathogenesis of systemic sclerosis","volume":"34","author":"Tsou","year":"2022","journal-title":"Curr Opin Rheumatol"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","article-title":"Senolytic CAR T cells reverse senescence-associated pathologies","volume":"583","author":"Amor","year":"2020","journal-title":"Nature"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"930970","DOI":"10.3389\/fimmu.2022.930970","article-title":"Can antinuclear antibodies have a pathogenic role in systemic sclerosis?","volume":"13","author":"Chepy","year":"2022","journal-title":"Front Immunol"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13075-018-1689-6","article-title":"Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts","volume":"20","author":"Raschi","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13075-020-02360-3","article-title":"Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis","volume":"22","author":"Raschi","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.autrev.2016.04.004","article-title":"Antibodies against angiotensin II type 1 receptor (AT1R) and endothelin receptor type A (ETAR) in systemic sclerosis (SSc)-response","volume":"15","author":"Riemekasten","year":"2016","journal-title":"Autoimmun Rev"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa052955","article-title":"Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis","volume":"354","author":"Baroni","year":"2006","journal-title":"N Engl J Med"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.3390\/ijms21145102","article-title":"Anti-CXCL4 antibody reactivity is present in systemic sclerosis (SSc) and correlates with the SSc type I interferon signature","volume":"21","author":"Lande","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000450949","article-title":"Disease manifestation and inflammatory activity as modulators of Th17\/Treg balance and RORC\/FoxP3 methylation in systemic sclerosis","volume":"171","author":"Almanzar","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.clim.2011.01.013","article-title":"Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis","volume":"139","author":"Fenoglio","year":"2011","journal-title":"Clin Immunol"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/art.40737","article-title":"Adoptive Treg cell therapy in a patient with systemic lupus erythematosus","volume":"71","author":"Dall\u2019Era","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","article-title":"Treg cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1084\/jem.20040139","article-title":"In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes","volume":"199","author":"Tang","year":"2004","journal-title":"J Exp Med"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jaut.2017.01.001","article-title":"Generation of human islet-specific regulatory T cells by TCR gene transfer","volume":"79","author":"Hull","year":"2017","journal-title":"J Autoimmun"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.3389\/fimmu.2017.01313","article-title":"Avidity and bystander suppressive capacity of human regulatory T cells expressing de novo autoreactive T-cell receptors in Type 1 diabetes","volume":"8","author":"Yeh","year":"2017","journal-title":"Front Immunol"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaut.2018.05.003","article-title":"Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells","volume":"92","author":"Kim","year":"2018","journal-title":"J Autoimmun"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/ajt.14185","article-title":"Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection","volume":"17","author":"Boardman","year":"2017","journal-title":"Am J Transplant"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1172\/JCI82771","article-title":"Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor","volume":"126","author":"MacDonald","year":"2016","journal-title":"J Clin Invest"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/ajt.14175","article-title":"Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor","volume":"17","author":"Noyan","year":"2017","journal-title":"Am J Transplant"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/mt.2014.41","article-title":"Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells","volume":"22","author":"Blat","year":"2014","journal-title":"Mol Ther"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1053\/j.gastro.2008.02.060","article-title":"Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice","volume":"134","author":"Elinav","year":"2008","journal-title":"Gastroenterology"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.4049\/jimmunol.1701800","article-title":"Targeting antigen-specific B cells using antigen-expressing transduced regulatory T cells","volume":"201","author":"Zhang","year":"2018","journal-title":"J Immunol"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1084\/jem.20080707","article-title":"Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity","volume":"205","author":"Zhou","year":"2008","journal-title":"J Exp Med"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.immuni.2008.05.007","article-title":"Molecular antagonism and plasticity of regulatory and inflammatory T cell programs","volume":"29","author":"Yang","year":"2008","journal-title":"Immunity"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jaci.2014.12.1932","article-title":"Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis","volume":"135","author":"MacDonald","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/nm.2848","article-title":"Lineage tracing and genetic ablation of ADAM12(+) perivascular cells identify a major source of profibrotic cells during acute tissue injury","volume":"18","author":"Dulauroy","year":"2012","journal-title":"Nat Med"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.stem.2014.11.004","article-title":"Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis","volume":"16","author":"Kramann","year":"2015","journal-title":"Cell Stem Cell"},{"key":"R56-20250526","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.stem.2022.08.012","article-title":"Vaccination-based immunotherapy to target profibrotic cells in liver and lung","volume":"29","author":"Sobecki","year":"2022","journal-title":"Cell Stem Cell"},{"key":"R57-20250526","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1016\/j.celrep.2016.11.011","article-title":"Immunometabolic pathways in BCG-induced trained immunity","volume":"17","author":"Arts","year":"2016","journal-title":"Cell Rep"},{"key":"R58-20250526","doi-asserted-by":"crossref","first-page":"aaf1098","DOI":"10.1126\/science.aaf1098","article-title":"Trained immunity: a program of innate immune memory in health and disease","volume":"352","author":"Netea","year":"2016","journal-title":"Science"},{"key":"R59-20250526","doi-asserted-by":"crossref","first-page":"5670","DOI":"10.1038\/s41467-019-13636-x","article-title":"Trained immunity modulates inflammation-induced fibrosis","volume":"10","author":"Jeljeli","year":"2019","journal-title":"Nat Commun"},{"key":"R60-20250526","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.3390\/cells11233912","article-title":"Hematopoietic cell transplantation for systemic sclerosis: a review","volume":"11","author":"Levin","year":"2022","journal-title":"Cells"},{"key":"R61-20250526","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2665-9913(19)30038-4","article-title":"The nosology of systemic sclerosis: how lessons from the past offer new challenges in reframing an idiopathic rheumatological disorder","volume":"1","author":"Lescoat","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"R62-20250526","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/annrheumdis-2019-215894","article-title":"Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile","volume":"79","author":"Skaug","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R63-20250526","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1136\/annrheumdis-2018-214865","article-title":"Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease","volume":"78","author":"Valenzi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R64-20250526","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/BOR.0000000000000747","article-title":"Novel classifications for systemic sclerosis: challenging historical subsets to unlock new doors","volume":"32","author":"Sobanski","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"R65-20250526","doi-asserted-by":"crossref","first-page":"e785","DOI":"10.1016\/S2665-9913(22)00217-X","article-title":"Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort","volume":"4","author":"Elhai","year":"2022","journal-title":"Lancet Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000970","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:21:23Z","timestamp":1748294483000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":65,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000970","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,29]]}}}